International Journal of Pediatrics

Acute Bronchiolitis Treatment: A Comparison of Montelukast, Aminophylline and Ventolin in Pediatric Patients: A Clinical Trial Study

Gholamreza Soleimani; Elham Shafighi Shahri; seyed hosein soleimanzadeh mousavi

Volume 9, Issue 6 , June 2021, , Pages 13683-13690

https://doi.org/10.22038/ijp.2020.51086.4055

Abstract

Background: The effects of various drugs on reducing the severity of bronchiolitis symptoms in children have been identified. We sought to make a comparison of Montelukast, Aminophylline ... Read More

The Efficacy of Montelukast in Adjunct with Amoxicillin in Treatment of Acute Otitis Media (AOM) in Children

Mohammad-Bagher Rahmati; Salehe Sabouri; Fatemeh Sabouri

Volume 5, Issue 1 , January 2017, , Pages 4257-4262

https://doi.org/10.22038/ijp.2016.7803

Abstract

BackgroundAcute otitis media (AOM) is very common in children. In spite of spontaneously relief, some cases suffer from the recurrence and other complications occurring after AOM. Animal ... Read More

Determine Efficacy of a Short Course of Montelukast in Children with Intermittent Asthma and Viral Infection

Hamid Ahanchian; Fatemeh Behmanesh; Hamid Reza Kianifar; Nasrin Sadat Motevalli; Seyed Ali Jafari

Volume 1, Issue 1 , August 2013, , Pages 25-29

https://doi.org/10.22038/ijp.2013.2030

Abstract

Introduction Mild intermittent asthma is common in children and viral infections are responsible for the majority of exacerbations. As leukotrienes are potent inflammatory mediators, ... Read More Introduction Mild intermittent asthma is common in children and viral infections are responsible for the majority of exacerbations. As leukotrienes are potent inflammatory mediators, some studies have shown that Montelukast, a leukotriene receptor antagonist, may be effective on reduction of asthma symptom. To determine whether a short course of Montelukast in asthmatic children with common cold would modify the severity of an asthma episode. Materials and Methods Children, aged 6-12 years with intermittent asthma participated in this randomized, double-blind, placebo-controlled clinical trial. Treatment with Montelukast or placebo was initiated at the onset of viral upper respiratory tract infection and continued for 7 days. Primary outcomes included the clinical manifestation: duration of episodes, daily symptom, nights symptoms and activity limitation. Secondary outcomes included the need for beta agonist usage, oral prednisolone, physician visit, hospital admission and school absence. Results A total of 187 children with intermittent asthma were randomized, 93 to Montelukast group and 94 to placebo group. Montelukast significantly decreased the cough by 17.3% (P<0.001), nighttime awakenings by 5.4% (P=0.01), interference with normal activity by 6% (P<0.01), time off from school by 6% (P<0.01), β-agonist usage by 17.2% (P<0.001) and doctor visits by12.2% (P<0.01) compared to placebo. Whereas there was a non significant reduction in wheezing, tachypnea, respiratory distress, asthma exacerbation, oral prednisolone and hospitalization (P=0.8). Conclusion A short course of Montelukast, introduced at the first sign of a viral infection, results in a reduction in cough, β-agonist use and nights awakened, time off from school and limitation of activity. More studies are needed to evaluate the optimal dose and duration of treatment.

International Journal of Pediatrics

Articles in Press

Current Issue

Volume 11 (2023)

Volume 10 (2022)

Volume 9 (2021)

Volume 8 (2020)

Volume 7 (2019)

Volume 6 (2018)

Volume 5 (2017)

Volume 4 (2016)

Volume 3 (2015)

Volume 2 (2014)

Volume 1 (2013)

Keywords = Montelukast

Acute Bronchiolitis Treatment: A Comparison of Montelukast, Aminophylline and Ventolin in Pediatric Patients: A Clinical Trial Study

Abstract

The Efficacy of Montelukast in Adjunct with Amoxicillin in Treatment of Acute Otitis Media (AOM) in Children

Abstract

Determine Efficacy of a Short Course of Montelukast in Children with Intermittent Asthma and Viral Infection

Abstract